Jingsheng Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jingsheng Yan has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Xian-Jin Xie
38 shared publications- David A. Boothman
Affiliation: Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
24 shared publications Long-Shan Li
20 shared publications- Erik A. Bey
Department of Biochemistry and Molecular Biology, School of Medicine, Indiana University, Indianapolis, Indiana
18 shared publications - Jin-Ming Gao
Northwest A&F University
18 shared publications - Amyn A. Habib
Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
14 shared publications
Latest Publications
- 1 March 2025
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 36 (11) , 1043-1053
Myeloid-derived suppressor cells in metabolic and cardiovascular disorders
- 1 March 2025
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 36 (11) , 1043-1053
Myeloid-derived suppressor cells in metabolic and cardiovascular disorders
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer
Ionizing radiation (IR) is a key therapeutic regimen for many head and neck cancers (HNC). However, the 5-year overall survival rate for locally advanced HNCs is approximately 50% and better therapeutic efficacy is needed. NAD(P)H:quinone oxidoreductase 1 (NQO1) is overexpressed in many cancers, and β-lapachone (β-lap), a unique NQO1 bioactivatable drug, exploits this enzyme to release massive reactive oxygen species (ROS) that synergize with IR to kill by programmed necrosis. β-Lap represents a novel therapeutic opportunity in HNC leading to tumor-selective lethality that will enhance the efficacy of IR. Immunohistochemical staining and Western blot assays were used to assess the expression levels of NQO1 in HNC cells and tumors. Forty-five percent of endogenous HNCs expressed elevated NQO1 levels. In addition, multiple HNC cell lines and tumors demonstrated elevated levels of NQO1 expression and activity and were tested for anticancer lethality and radiosensitization by β-lap using long-term survival assays. The combination of nontoxic β-lap doses and IR significantly enhanced NQO1-dependent tumor cell lethality, increased ROS, TUNEL-positive cells, DNA damage, NAD+, and ATP consumption, and resulted in significant antitumor efficacy and prolonged survival in two xenograft murine HNC models, demonstrating β-lap radiosensitization of HNCs through a NQO1-dependent mechanism. This translational study offers a potential biomarker-driven strategy using NQO1 expression to select tumors susceptible to β-lap–induced radiosensitization. Mol Cancer Ther; 15(7); 1757–67. ©2016 AACR.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer
Ionizing radiation (IR) is a key therapeutic regimen for many head and neck cancers (HNC). However, the 5-year overall survival rate for locally advanced HNCs is approximately 50% and better therapeutic efficacy is needed. NAD(P)H:quinone oxidoreductase 1 (NQO1) is overexpressed in many cancers, and β-lapachone (β-lap), a unique NQO1 bioactivatable drug, exploits this enzyme to release massive reactive oxygen species (ROS) that synergize with IR to kill by programmed necrosis. β-Lap represents a novel therapeutic opportunity in HNC leading to tumor-selective lethality that will enhance the efficacy of IR. Immunohistochemical staining and Western blot assays were used to assess the expression levels of NQO1 in HNC cells and tumors. Forty-five percent of endogenous HNCs expressed elevated NQO1 levels. In addition, multiple HNC cell lines and tumors demonstrated elevated levels of NQO1 expression and activity and were tested for anticancer lethality and radiosensitization by β-lap using long-term survival assays. The combination of nontoxic β-lap doses and IR significantly enhanced NQO1-dependent tumor cell lethality, increased ROS, TUNEL-positive cells, DNA damage, NAD+, and ATP consumption, and resulted in significant antitumor efficacy and prolonged survival in two xenograft murine HNC models, demonstrating β-lap radiosensitization of HNCs through a NQO1-dependent mechanism. This translational study offers a potential biomarker-driven strategy using NQO1 expression to select tumors susceptible to β-lap–induced radiosensitization. Mol Cancer Ther; 15(7); 1757–67. ©2016 AACR.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer
Ionizing radiation (IR) is a key therapeutic regimen for many head and neck cancers (HNC). However, the 5-year overall survival rate for locally advanced HNCs is approximately 50% and better therapeutic efficacy is needed. NAD(P)H:quinone oxidoreductase 1 (NQO1) is overexpressed in many cancers, and β-lapachone (β-lap), a unique NQO1 bioactivatable drug, exploits this enzyme to release massive reactive oxygen species (ROS) that synergize with IR to kill by programmed necrosis. β-Lap represents a novel therapeutic opportunity in HNC leading to tumor-selective lethality that will enhance the efficacy of IR. Immunohistochemical staining and Western blot assays were used to assess the expression levels of NQO1 in HNC cells and tumors. Forty-five percent of endogenous HNCs expressed elevated NQO1 levels. In addition, multiple HNC cell lines and tumors demonstrated elevated levels of NQO1 expression and activity and were tested for anticancer lethality and radiosensitization by β-lap using long-term survival assays. The combination of nontoxic β-lap doses and IR significantly enhanced NQO1-dependent tumor cell lethality, increased ROS, TUNEL-positive cells, DNA damage, NAD+, and ATP consumption, and resulted in significant antitumor efficacy and prolonged survival in two xenograft murine HNC models, demonstrating β-lap radiosensitization of HNCs through a NQO1-dependent mechanism. This translational study offers a potential biomarker-driven strategy using NQO1 expression to select tumors susceptible to β-lap–induced radiosensitization. Mol Cancer Ther; 15(7); 1757–67. ©2016 AACR.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer
Ionizing radiation (IR) is a key therapeutic regimen for many head and neck cancers (HNC). However, the 5-year overall survival rate for locally advanced HNCs is approximately 50% and better therapeutic efficacy is needed. NAD(P)H:quinone oxidoreductase 1 (NQO1) is overexpressed in many cancers, and β-lapachone (β-lap), a unique NQO1 bioactivatable drug, exploits this enzyme to release massive reactive oxygen species (ROS) that synergize with IR to kill by programmed necrosis. β-Lap represents a novel therapeutic opportunity in HNC leading to tumor-selective lethality that will enhance the efficacy of IR. Immunohistochemical staining and Western blot assays were used to assess the expression levels of NQO1 in HNC cells and tumors. Forty-five percent of endogenous HNCs expressed elevated NQO1 levels. In addition, multiple HNC cell lines and tumors demonstrated elevated levels of NQO1 expression and activity and were tested for anticancer lethality and radiosensitization by β-lap using long-term survival assays. The combination of nontoxic β-lap doses and IR significantly enhanced NQO1-dependent tumor cell lethality, increased ROS, TUNEL-positive cells, DNA damage, NAD+, and ATP consumption, and resulted in significant antitumor efficacy and prolonged survival in two xenograft murine HNC models, demonstrating β-lap radiosensitization of HNCs through a NQO1-dependent mechanism. This translational study offers a potential biomarker-driven strategy using NQO1 expression to select tumors susceptible to β-lap–induced radiosensitization. Mol Cancer Ther; 15(7); 1757–67. ©2016 AACR.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma
PDF file - 23K, Radiosensitization of normal human astrocytes (NHA) with NVP-BEZ235.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma
PDF file - 23K, Radiosensitization of normal human astrocytes (NHA) with NVP-BEZ235.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma
PDF file - 92K, NVP-BEZ235 does not interfere with the anti-tumor effects of TMZ in U87-vIII tumors.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma
PDF file - 92K, NVP-BEZ235 does not interfere with the anti-tumor effects of TMZ in U87-vIII tumors.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma
PDF file - 523K, NVP-BEZ235 inhibits the DDR in GBM9 neurospheres.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma
PDF file - 523K, NVP-BEZ235 inhibits the DDR in GBM9 neurospheres.